治疗慢性阻塞性肺疾病新型吸入剂——Duaklir Pressair  

A novel inhaler for chronic obstructive pulmonary disease—Duaklir Pressair

作　　者：张万年 于芳 米春来 ZHANG Wan-nian;YU Fang;MI Chun-lai(School of Petrochemical Engineering,Liaoning Shihua University,Liaoning Fushun 113001,China;Beijing Anjianxi Pharmaceutical Technology Co.,Ltd.,Beijing 100036,China)

机构地区：[1]辽宁石油化工大学石油化工学院,辽宁抚顺113001 [2]北京安健熹医药科技有限公司,北京100036

出　　处：《临床药物治疗杂志》2022年第5期12-16,共5页Clinical Medication Journal

摘　　要：Duaklir Pressair是由长效毒蕈碱拮抗剂阿地溴铵(Aclidinium Bromide)和长效β2受体激动剂富马酸福莫特罗(Formoterol Fumarate)组成的固定剂量组合产品,是一种新型的呼吸驱动多剂量干粉吸入剂。美国食品药品管理局批准其用于慢性阻塞性肺疾病患者的长期治疗。该药需要通过预加载、呼吸驱动的Pressair多剂量吸入器给药,只需每日2次即可,患者可以通过独特的干粉吸入器最大限度地改善肺功能。本文对Duaklir Pressair的基本信息、药理作用、药物代谢动力学、临床疗效、安全性、用法用量和药物相互作用等方面进行综述。Duaklir Pressair,a fixed-dose combination of Aclidinium Bromide(an anticholinergic)and Formoterol Fumarate(a long-acting selective beta 2-adrenergic agonist),is a novel breath-actuated multi-dose dry powder inhale.The Food and Drug Administration of the United States approved Duaklir Pressair for the chronic obstructive pulmonary disease(COPD).The drug needs to be administered via a preloaded,breath-actuated Pressair multi-dose inhaler,which can be administered only twice a day,and patients can maximize lung function with the unique dry powder inhaler.This review summarizes the basic information,pharmacological action,pharmacokinetics,clinical efficacy,safety,usage,dosage and drug interaction of Duaklir Pressair.

关 键 词：Duaklir Pressair 阿地溴铵 富马酸福莫特罗 慢性阻塞性肺疾病 

分 类 号：R974[医药卫生—药品]